Twenty patients were identified, representing 23 individual anatomic targets treated between May 2006 and April 2008. Details identified included radiation treatment specifications, pre- and post-SBRT CT/ [18F] fluorodeoxyglucose-positron emission tomography (FDG)-PET scans, serum liver function tests,

and follow-up clinic exams. A Whole-Body Vaclock (Med-Tec), a device that immobilizes the patient by creating a rigid, conformal mold around the patient’s body as well as utilizing straps around the patient, was used for each patient at the time of simulation. Next, a pancreatic protocol 3D CT scan was performed with the patient in the treatment position. If respiratory motion was anticipated, #BMS-907351 price keyword# Inhibitors,research,lifescience,medical a 4D CT “gated” scan was performed using the Real-time Position Management system (Varian) and images were transferred to the 4D workstation (GE Medical) for motion analysis. The images from the CT scan (3D and/or gated) were then transferred from the workstation to the Eclipse Treatment Planning System (Varian) for stereotactic Inhibitors,research,lifescience,medical radiation planning. Response analysis The response rate and toxicity data were analyzed using Kaplan-Meier statistics.

Response to treatment was determined by comparing pre-SBRT and post-SBRT CT and FDG-PET scans at various intervals after SBRT. Each scan was individually reviewed, and tumor size measurements were Inhibitors,research,lifescience,medical determined by an individual observer and compared to the official radiology report. Tumor size on CT was determined by the product of the maximal orthogonal diameters. Maximum SUV values were based on the

official report. Definitions of response were based on a combination of RECIST criteria and the revised lymphoma response criteria (20)-(22). Complete Response (CR) = complete resolution of FDG activity (to background levels) on PET with no increase in size on CT. Partial Response (PR) ≥ 30% decrease in diameter product of lesion on CT, with no increase in mean SUV on FDG-PET; or >10% decrease in mean SUV on PET with no increase in diameter Inhibitors,research,lifescience,medical product of lesion on CT. Progressive Disease (PD) ≥ 25% increase in diameter product of lesion on CT, or >10% increase in mean SUV on FDG-PET. Stable Disease (SD) = does not meet GBA3 criteria for CR, PR, or PD. Local Control (LC) = (CR + PR + SD). Follow-up clinical visits at 1 week and 1 month were used to asses for acute symptomatic toxicity. Acute GI toxicity was scored based on the Common Terminology Criteria for Adverse Events version 3.0. For patients with liver metastases, or those patients with target volumes encompassing any portion of the liver, serum liver function tests (AST, ALT, and alkaline phosphatase) were drawn pre-and post-SBRT at 1 week and 1 month per a related institutional phase I dose escalation protocol. Liver toxicity was graded according to the RTOG Cooperative Group Common Toxicity Criteria.